[CAS NO. 239101-33-8] Deferitrin
PRODUCTS SPECIFICATIONS [239101-33-8]
DESCRIPTION [239101-33-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 253.27 |
| Molecular Formula | C11H11NO4S |
| SMILES | O=C([C@]1(C)N=C(C2=CC=C(O)C=C2O)SC1)O |
Summary
In Vitro
The iron-clearing efficiency (ICE) of Deferitrin (GT-56-252) in a non-iron-overloaded rodent model after oral (po) administration at 300 µmol/kg is shown to be 1.1% [1] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00069862 | Genzyme, a Sanofi Company|Sanofi |
Beta-Thalassemia
|
September 2003 | Phase 1|Phase 2 |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
DMSO : 125 mg/mL ( 493.54 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.9484 mL | 19.7418 mL | 39.4836 mL |
| 5 mM | 0.7897 mL | 3.9484 mL | 7.8967 mL |
| 10 mM | 0.3948 mL | 1.9742 mL | 3.9484 mL |
References
- [1] Raymond J Bergeron, et al. Design, Synthesis, and Testing of Non-Nephrotoxic Desazadesferrithiocin Polyether Analogues. J Med Chem. 2008 Jul 10;51(13):3913-23.
- [2] Joanne M Donovan, et al. Preclinical and Clinical Development of Deferitrin, a Novel, Orally Available Iron Chelator. Ann N Y Acad Sci. 2005;1054:492-4.
